Omzo vs bmiMD: Compare Compounded GLP-1 Plans, Price & Shipping
If you need a direct comparison of Omzo vs bmiMD, the core trade offs are clinician-guided compounded semaglutide and tirzepatide at Omzo with starting prices, versus bmiMD focusing on compounded tirzepatide with multi-month pricing and free shipping. Early verdict: choose Omzo if you want clinician-guided plans and access to semaglutide options; choose bmiMD if you want tirzepatide with lower long-term monthly rates and free shipping.
Explore Omzo clinician-guided plans
Overview: Omzo vs bmiMD at a glance
Both providers offer clinician-reviewed telehealth for GLP-1 or GLP-1/GIP therapy and rely on state-licensed compounding pharmacies when compounded medications are used. Important regulatory note for both: compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The two most visible differences in the evidence are medication variety, pricing structure, and shipping or subscription terms.
Key difference 1: Medication options and clinician guidance
Omzo emphasizes clinician-guided GLP-1 care and lists both compounded semaglutide and tirzepatide as available through its platform. The Omzo site states clinicians determine eligibility and may prescribe compounded medications or write prescriptions for branded medications that the patient fills elsewhere.
bmiMD centers its offering on compounded tirzepatide (GLP-1/GIP) with clinician review and 24/7 clinician access. bmiMD’s evidence focuses on tirzepatide specifically and its subscription options rather than semaglutide.
Key difference 2: Pricing model and commitments
Omzo presents starting prices for specific medications: semaglutide starting at $179 and tirzepatide starting at $279. Pricing is presented as starting amounts and Omzo notes that medication costs are included in the fees they collect, with clinicians making final prescribing decisions.
bmiMD publishes tiered monthly pricing for tirzepatide with explicit month-to-month and multi-month equivalents: $179 for a one-month plan, $159 per month for a three-month plan, $149 per month for a six-month plan, and $139 per month for a 12-month plan. bmiMD notes the lowest price requires a 12-month commitment and that total prepaid charges should be confirmed.
View bmiMD tirzepatide subscription options
Key difference 3: Shipping, refills, and access
Omzo advertises fast, discreet delivery and indicates FSA and HSA eligibility for its programs, while noting that if a branded medication is prescribed the patient must fill that prescription at a pharmacy of their choice.
bmiMD includes free shipping on every subscription order and highlights online refills and delivery. bmiMD also promotes 24/7 clinician access as part of its service model.
Comparison table: Omzo vs bmiMD
| Criteria | Omzo | bmiMD |
|---|---|---|
| Primary offerings | Compounded semaglutide and tirzepatide; clinician-guided | Compounded tirzepatide (GLP-1/GIP) |
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | Tirzepatide $179/month (one-month option) |
| Multi-month pricing | Not supplied | $159/mo (3 mo), $149/mo (6 mo), $139/mo (12 mo) |
| Shipping | Fast, discreet delivery; FSA & HSA eligible | Free shipping on every subscription order |
| Clinician access | Clinician-guided plans reviewed by licensed U.S. providers; providers determine eligibility | 24/7 clinician access; treatments available only when clinician determines medically appropriate |
| Regulatory note | Compounded medications are not FDA-approved and not reviewed by FDA | Compounded medications are not FDA-approved and not reviewed by FDA |
How prescribing and fulfillment differ
Omzo states its platform connects users with licensed U.S. providers who may prescribe compounded medications prepared and shipped by a state-licensed sterile compounding pharmacy. Omzo also notes providers may write prescriptions for branded medications that Omzo does not sell or ship and that patients would fill at their chosen pharmacy.
bmiMD states medications are prepared in a state-licensed pharmacy and delivered to your door, with confirmations to maintain target strength and independent verification in FDA- and DEA-registered labs mentioned in landing evidence. bmiMD highlights a 100% refundable policy if a user is not eligible for the program according to their posted claims.
See Omzo medication and shipping details
Safety, claims, and results language
Both providers include disclaimers that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Omzo explicitly says individual results may vary and that the platform is not a medical practice; clinicians make final prescribing decisions. bmiMD also frames treatment as available only when a licensed clinician determines it is medically appropriate.
Check bmiMD eligibility and terms
Conclusion: Omzo vs bmiMD
Omzo vs bmiMD presents a clear divide: Omzo emphasizes clinician-guided plans with both semaglutide and tirzepatide options and starting price points, while bmiMD focuses on compounded tirzepatide with a subscription model that reduces the monthly equivalent for longer commitments and includes free shipping. Both note compounded medications are not FDA-approved and require clinician determination.
Choose Omzo if you want clinician-guided access to both compounded semaglutide and tirzepatide and the option for providers to write prescriptions for branded medications that you can fill separately.
Choose bmiMD if you want compounded tirzepatide with explicit multi-month pricing, lower long-term monthly equivalents, free subscription shipping, and online refills.